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Long‑term efficacy of BCG 
vaccination in goat herds 
with a high prevalence 
of tuberculosis
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Zoraida Cervera1, Irene Mercader4, Sergio López‑Soria1, Mariano Domingo1,2 & 
Bernat Pérez de Val1
Vaccination of goats against tuberculosis (TB) has been promoted as an ancillary tool for controlling 
the disease in infected livestock herds. A three‑year trial to assess the efficacy of BCG vaccine was 
carried out in five goat herds. At the beginning of the trial (month 0), all animals were tested for TB 
using thee different diagnostic tests. Animals negative to all tests were vaccinated with BCG and all 
replacement goat kids were also systematically vaccinated throughout the trial. All animals were 
tested by Interferon‑gamma release assay (IGRA) using vaccine compatible reagents at months 6, 
12, 24, and 36. The risk factors for TB infection were also evaluated. At the end of the study, four 
out of five farms showed variable reductions of the initial prevalence (93.5%, 28.5%, 23.2%, and 
14.3% respectively), and an overall incidence reduction of 50% was observed in BCG vaccinated 
goats, although adult vaccinated goats showed higher incidences than vaccinated goat kids. The 
unvaccinated positive animals remaining in herds and adult BCG vaccinated goats significantly 
enhanced the risk of infection in vaccinated animals. A systematic vaccination of goats with BCG, 
together with the removal of positive unvaccinated animals, may contribute to reducing the TB 
prevalence in goat herds.
Caprine tuberculosis (TB) is an infectious disease caused by different members of the Mycobacterium tuberculosis 
complex (MTBC), mainly by Mycobacterium caprae and Mycobacterium bovis1–3. Infected goats participate in 
the epidemiology of animal TB in multi-host  settings4–8 and pose a risk of zoonotic  TB9.
In addition, goat TB in endemic herds implies large economic losses due to the reduction of milk produc-
tion in TB infected  goats10, and to trade restrictions and depopulation of positive  herds11,12. In underdeveloped 
countries or high TB prevalent settings (such as Spain), eradication programs based only on test and slaughter 
are not always the best cost-effective strategy. In this regard, vaccination of goats against TB has been promoted 
as an ancillary tool for reducing TB  prevalence13.
The M. bovis bacillus Calmette-Guérin (BCG), the only TB licensed vaccine in humans, and badgers in the 
United Kingdom, has been demonstrated to be safe and relatively inexpensive to  produce14. The efficacy of BCG 
against TB has been evaluated in some livestock and wildlife  species15, yielding variable  results15. A few field trials 
have been conducted in  cattle16–20,  goats21, and  wildlife22,23. Although protection was incomplete, encouraging 
results were observed in reducing the extent of lesions and the transmission of TB.
One of the major challenges for BCG vaccination in livestock is its interference with TB current diagnostic 
tests, namely the single intradermal test (SIT) or the single intradermal cervical comparative tuberculin test 
(SICCT) and the Interferon-gamma (IFN-γ) release assay (IGRA). Antigens to differentiate infected from vac-
cinated animals (DIVA) have been developed in the two last decades to overcome these  interferences24 and were 
evaluated in goats in both infection and vaccination  settings25–27.
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Finally, identifying factors that increase or reduce the persistence of TB in infected herds become crucial 
for eradicating and controlling strategies. Herd size, housing type, or feeding practices have been identified as 
risk factors for TB persistence in cattle  herds28,29. Even though previous experimental studies demonstrated that 
BCG vaccination of goats confers protection against  TB30–32, the factors influencing TB persistence should be 
disclosed to assess the efficacy of vaccination strategies at a herd level.
The present study aimed to assess the efficacy of BCG vaccination during three years in five goat farms at a 
herd level and among vaccination batches, and the identification of the risk factors that may influence the efficacy 
of a vaccination program for the control of TB in goats.
Results
Vaccine efficacy at a herd level. The evolution of TB prevalence and the prevalence reduction estimated 
on the basis of the attributable fraction (AF) were variable among farms throughout the vaccine trial (Fig. 1). At 
the end of the trial (month 36), a favorable outcome was observed in four out of five farms. Overall AF (from 
month 0 to month 36) of 93.5%, 28.5% and 23.2% were obtained in farms 1, 2, and 3, respectively (Fig. 1a–c). In 
farm 5, there was a dramatic decrease in the census in the six first months of the trial (from 174 to 135 animals), 
and the prevalence raised from 46.0% at month  (M) 0 to 60.7% at M6. The overall AF in farm 5 was 14,32% 
(Fig. 1e). In farm 4, the percentage of positive animals remained stable until M12 (~ 33%) but increased to 46.5% 
from M12 to M36. Thus, no prevalence reduction was obtained in farm 4 (Fig. 1d). The overall results of the 
five farms are represented in Fig. 1f. Altogether, the overall initial prevalence (M0 = 41%) started to drop at M6 
(37.1%), remained stable at M12 (38.3%) and M24 (38.1%), and continued to drop at M36 (33.6%). The overall 
AF between M0 and M36 in the five farms was 18.1%.
Farms 1, 2, 3, and 5 showed a significant overall reduction of TB positive animals (P < 0.001, chi-square test), 
passing from 546 TB positives out of 1255 goats at M0 (i.e. 43.5% of TB positive animals) to 451 out of 1506 at 
M36 (303 TB positive goats vaccinated and 148 TB positive unvaccinated goats), with an overall percentage of 
prevalence reduction (AF) of 31% at the end of the study. The overall prevalence (% of TB positive animals) and 
AF of these four farms that showed a favourable vaccination outcome are summarized in Table 1. The overall pro-
portion of TB-infected animals significantly decreased at each sampling time point while the AF increased. The 
evolution of the goat census in terms of TB status in farms is shown in Fig. 2. In farms with a positive outcome, at 
M36, the unvaccinated animals that remained in the herds represented 32.8% of the total of TB positive animals. 
The vast majority of goats (90.2%) from these farms were vaccinated, and 77.7% of them remained TB negative. 
The incidence (Ia) of TB in BCG vaccinated goats from farms was also calculated (Table 2). The overall data 
from all five farms did not show reductions in the incidence between samplings. In farms with a favourable 
outcome (farms 1, 2, 3, and 5), in general, there was a progressive reduction of incidence between sampling 
time points, until the end of the trial, and a 50% of overall incidence reduction was observed from M6 to M36.
Efficacy of BCG in the different vaccinated batches. At the end of the trial, in farms 1, 2, 3, and 5, 
adult goats vaccinated at the beginning of the study showed a higher proportion of TB positive animals com-
pared to the goat kids vaccinated at 2–3 months of age (Table 3).
The evolution of TB status throughout the trial in BCG vaccinated batches is shown in Fig. 3. Among farms, 
adult goats vaccinated at M0 (Batch B-0) showed the highest TB incidence during the first year in contact with 
infected animals of the herd regardless of the farm (Fig. 3, B-0 showed the highest decrease in the proportion 
of TB negative animals during this period). In farms 1, 2, and 5, all batches of vaccinated goat kids (B-06, B-12, 
B-24, and B-36) showed a low risk of infection irrespectively of the time of contact, with incidences between 
periods ranging from 0% to 3.5%, 0% to 10% and 6.25% to 9.23%%, for farms 1, 2 and 5, respectively (Fig. 3 a, 
b and e). In farm 3 (Fig. 3c), the proportion of TB negative adult vaccinated goats at M0 (Batch B-0), and goat 
kids vaccinated at M0 (Batch B-06) decreased dramatically after the first year of contact, with only 54% and 
69% of goats remaining TB negative, respectively. After three years of contact, only 35% and 38% of individuals 
from batches B-0 and B-06, respectivley, remained TB negative. In addition, in batch B-12 (goat kids vaccinated 
during the first year of the trial), the proportion of TB negatives dropped to 57% after three years of contact. In 
contrast, the proportion of TB negative animals in batches B-24 and B-36 (goat kids vaccinated in the second and 
third year of the trial), that were in the in contact for two and one years of study, respectively, were 77.5% and 
93%, respectively. In farm 4 (Fig. 3d), after three years of contact, the proportion of TB negatives within adult 
vaccinated goats (B-0) decreased to reach a 36% and in animals vaccinated when goat kids, B-06, B-12, decreased 
to 13% and 47%, respectively. In batches B-24 and B-36, after two and one years of exposure, the proportion of 
TB negatives was 42% and 83%, respectively.
The TB incidence risk was evaluated using the multilevel model with the lowest AIC. Results of the paired 
comparisons between batches of the four farms during the first year in contact with the TB positive herd are 
described in Table 4. The risk of TB in batch B-0 (adult goats vaccinated at M0) during the first year of contact 
was significantly higher compared to three out of the four batches of vaccinated goat kids (B-06, B-24 and B-36). 
No differences were observed among batches vaccinated when goat kids, neither among batches after two or 
three years of contact with TB positive herds regardless of the age of vaccination.
Factors influencing the incidence of TB in vaccinated animals. The generalized mixed-effect model 
of each risk factor showed that the qualitative variable of ventilation facilities (high or low), and four quantitative 
variables (the initial prevalence, the number of positive unvaccinated animals remaining in herds, the number 
of adult BCG vaccinated TB positive goats at the end of the study and, the number of BCG vaccinated TB posi-
tive goat kids at the end of the study) potentially influenced the incidence in vaccinated animals. Thus, these six 
variables were included in the multilevel model. The initial census and management (intensive or extensive) did 
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Figure 1.  Evolution of prevalence throughout the BCG vaccination trial. Evolution of census (grey bars), 
prevalence (red lines) and percentage of prevalence reduction (blue lines) in farms 1 (a), 2 (b), 3 (c), 4 (d) and 
5 (e), and overall reduction of five farms (f). The prevalence was measured as the percentage (%) of TB positive 
animals = number of TB positive goats / total census. The reduction of prevalence was measured as attributable 
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not show any relevant effect (P > 0.3) at the individual analysis and thus, were discarded for the multilevel model. 
Based on the multilevel model with the lowest AIC, the number of positive unvaccinated animals remaining in 
herds and the number of positive adult vaccinated goats (B-0) were significant risk factors (P < 0.05) for TB infec-
tion in BCG vaccinated animals. The initial herd prevalence was still not a significant TB risk factor (P < 0.1). 
The other parameters included in the model were not detected as significant risk factors for TB infection in BCG 
vaccinated goat herds.
Discussion
In this field study, the efficacy of long-term vaccination with BCG of adult and replacement goat kids was evalu-
ated. The vaccine efficacy was determined as the reduction of prevalence, the AF, and the reduction of incidence 
of each herd during three years, by using IGRA responses against DIVA antigens. The results of vaccine efficacy 
were heterogeneous among farms, similar to that observed in previous human  studies33, varying from substantial 
to absence of protection. Taking into account the data from all farms, the moderate vaccine efficacy observed 
in the present study was similar to that observed in a systematic review of BCG vaccination trials in  children34. 
Protection of goat kids against TB with BCG has been previously reported in a preliminary study conducted in 
field conditions, as a reduction in the number of animals with TB lesions in the vaccinated group compared to 
the unvaccinated one (35% and 77%, respectively), after 18 months of exposure to natural infection in the  herd21. 
In the light of these results, the present study was aimed to assess the long-term efficacy of a blanket vaccination 
program, in a real field situation with productive goats, in which all susceptible animals (TB negative adults and 
replacement goat kids) were vaccinated. Four out of five goat farms (farm1, 2, 3, and 5) showed a favourable 
outcome in terms of vaccine efficacy (AF, prevalence and incidence reductions), with a majority of vaccinated 
animals remaining negative. Other field trials to assess BCG efficacy in cattle showed an even higher proportion 
of protected animals, although it was determined using different parameters. Thus, protections of 77.9% and 
67.4%, measured as TB lesions and bacterial load reduction, were observed in subcutaneously (BCG 3 × 105 CFU) 
and orally (BCG 1 × 108 CFU) vaccinated cattle,  respectively17,18.
Comparisons of BCG efficacy between field trials should be addressed with caution since the studies were 
conducted under different conditions, animals were exposed to different TB infection rates, and efficacy was 
measured using different parameters. Here, the initial TB prevalence of farms ranged between 33–63%, whereas 
in cattle studies, the herds had a proportion of TB positive reactors under 6%. These differences in herd TB preva-
lence may explain the higher BCG efficacy rates described in cattle than in the present study in goats. Another 
explanatory factor is the apparent higher intra-herd transmission of TB within the goat herds of the present study. 
Most of the herds (four out of five) had highly intensive management which implies that animals are grouped, 
often in high densities, and usually remaining in buildings with or without access to the outdoors, in contrast 
to extensive management where densities are low and animals usually have permanent access to outdoors for 
grazing. Thus, this intensive management in farms may have entailed closer contact among animals, with the 
exception of farm 1, in which the vaccine showed the highest protection rate and the management was extensive.
Even though BCG vaccination does not provide full protection against TB, it reduces the transmission of 
 MTBC15. Previous field and experimental studies in cattle and goats showed that BCG decreased either mycobac-
terial  shedding16 or TB  pathology20,21,31. Different practices may affect the evolution of incidence and prevalence 
among goat farms. All farmers discarded (more or less intensively) the old unvaccinated TB positive animals 
(results of tests were made available) for the slaughterhouse, which is one of the most common control measures. 
In this sense, Ameni and collaborators suggested that gradual removal of positive animals and their replacement 
by BCG vaccinated cattle, can be a valuable approach for TB control when intensive test and cull of positive 
animals is not  affordable19. Accordingly, the transmission of M. caprae in the present field trial, measured as TB 
incidence in vaccinated animals, was progressively reduced in four out five farms, attaining an overall reduction 
of 50% (Table 2).
Intriguingly, in farm 5, even with a positive outcome at the end of the trial, the initial prevalence increased 
six months after vaccination. In this case, a reduction of the census and a raise of incidence among vaccinated 
goats were observed. This farm had the lowest census among farms from the study and these fluctuations in the 
number of animals had a high impact on the prevalence outcome. Some deaths might be explained by productive 
reasons (8 goats from B-0 were discarded) and by the cold weather, which can worsen the symptoms of respira-
tory  diseases35. These weather conditions might force the farmer to maintain animals enclosed. In this particular 
case, the buildings had poor airflow, and the proximity between animals probably promoted TB transmission 
and other respiratory pathogens. To our disappointment, the vaccine failed to confer protection on farm 4. A 
single factor cannot explain this outcome. However, the results lead us to speculate that the most likely cause 
of vaccine failure might be that some batches of goat kids could be infected before vaccination. Those animals 
Table 1.  Overall evolution of TB status of farms 1, 2, 3 and 5 throughout 36 months of vaccination trial. 
a Attributable Fraction: Percentage of prevalence reduction between prevalence at M0 and the prevalence at 
subsequent samplings. Ranges are shown in parenthesis. * P < 0,05. ** P < 0,001. Chi square test. Significant 
differences respect to the initial proportion of positive animals at M0.
Month 0 Month 6 Month 12 Month 24 Month 36
Total Census 1255 1387 1335 1345 1506
% TB + animals 44% (33–63) 39% (23–61)* 39% (5–65)* 35% (1–57)** 30% (2–48)**
Attributable  fractiona – 11% (0–32) 11% (0–85) 19% (0–97) 31% (14–94)
5
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20369  | https://doi.org/10.1038/s41598-020-77334-1
www.nature.com/scientificreports/
were vaccinated after two months of age, most of them were in contact with adult goats after birth, and were 
potentially fed with unpasteurized colostrum. Nevertheless, overall findings suggest that the BCG vaccine is 
effective in reducing TB prevalence in goat farms. However, its effects are highly influenced by intrinsic factors 
of the farm (i.e., management practices, facilities, etc.).
The direct effect of vaccination among batches was also evaluated. For that purpose, incidence and time to 
IFN-γ conversion (DIVA test) of each animal were measured. TB incidence in adult vaccinated goats (batch 
B-0) was higher compared to vaccinated goat kids (batches B-06, B-24, and B36), mainly during the first year in 
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Figure 2.  Proportion of TB positive and BCG vaccinated goats from farms 1 (a), 2 (b), 3 (c), 4 (d), 5 (e) and all 
farms (f) throughout the trial. Evolution of population of vaccinated goats TB negative (light grey), vaccinated 
TB positive goats (dark grey) and unvaccinated animals (black) during the 36 months (M) of trial.
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against M. bovis  challenge36. The lack of efficacy of BCG in adult buffaloes was probably due to contact with 
environmental mycobacteria (EM). Indeed, adult goats had more chances to be sensitized by the exposure to 
EM prior to vaccination than goat kids. Contact with EM before BCG vaccination was associated with reduced 
vaccine efficacy in  cattle37 and  humans38. In addition, goats from five farms were usually infected by helminths. 
Pre-existing infections with helminths may reduce the efficacy of vaccines against  TB39,40. Indeed, BCG vacci-
nated cattle co-infected with Fasciola hepatica and M. bovis showed lower IFN-γ responses against PPD-B and 
reduced the number of reactors to SICCT 41. Helminthic infections usually drift the immune response towards 
a type T-helper 2 response and downregulate the T-helper  142. The latter immune response is necessary for the 
production of IFN-γ and effective responses against M. bovis43. These responses are triggered after BCG vaccina-
tion, but it seems that pre-existing infections with helminths do not lead to the development of those  responses43. 
Another relevant factor that cannot be ruled out is that some animals vaccinated at the beginning of the study 
(B-0) after showing a negative result to the IFN-γ DIVA test could be false negatives. In fact, chronic TB infections 
inducing anergy have been observed early in life in  goats44 and in young  calves45 probably due to the exhaustion 
of antigen-specific cell-mediated immune responses against the mycobacteria after a long period of  infection46.
The multilevel model detected a higher risk of TB infection in adult vaccinated goats (B-0) during the first 
year in contact with the TB positive herd. The risk was significantly higher compared to B-6, B-24, and B-36. 
Differences between B-0 and B12 were not significant, probably because only two farms had a batch B-12, and 
the number of goats in this batch was low (see Fig. 3a and 3c). These findings also reinforce the hypothesis 
that vaccination of adult goats could be less effective. In addition, the incidence and the risk of TB infection in 
replacement goats detected by the multilevel model were similar regardless of the time of contact and the batch 
of vaccinated goat kids. Nonetheless, after one year of contact, the risk of TB infection was similar among batches 
irrespectively of the age of vaccination. Thus, the protective immunity of BCG vaccination decayed after one 
year. In the same way, in BCG vaccinated cattle, no significant protection by the reduction in gross pathology was 
observed after challenge with M. bovis after 24 months of BCG  vaccination47,48. However, significant protection 
was still detected when the challenge was carried out at 12 months post-vaccination47. Here, despite a decrease in 
BCG vaccine efficacy after one year of vaccination regardless of the batch, some degree of individual protection 
may remain, and systematic vaccination of replacement goat kids, progressively reduced the TB prevalence, as 
observed in oral BCG vaccinated  badgers23. It suggests that high vaccination coverage may increase the protec-
tion against TB infection within the herd and improve the vaccine efficacy. Even so, other strategies to boost the 
protective immunity against TB, such as BCG revaccination, that showed improved protection than the single-
dose regime in  cattle48, might be further explored in large scale field trials.
On the other hand, as mentioned before, other control measures and intrinsic factors from farms may con-
tribute to the control of TB and may favour the success or failure of the vaccine program. In this context, the 
multilevel model was also used to evaluate different factors influencing the TB incidence among farms. The TB 
positive unvaccinated animals remaining in the herds and the adult vaccinated goats were identified as the two 
factors that increased the risk of TB cases in herds. As expected, initial TB positive animals were a source of 
infection for vaccinated animals. Indeed, some adult animals, probably chronically infected, may act as super 
 shedders49. Regarding the risk of adult vaccinated goats, as previously observed in humans, vaccination of adults 
was not  protective33. Moreover, as discussed above, it is possible that some vaccinated animals were anergic before 
BCG vaccination, which is a phenomenon that can appear relatively early in goats (at 2–3 years of age)44. Thus, 
despite vaccination, in our conditions, adult vaccinated goats may act as the unvaccinated goats, contributing 
to the spread of the TB infection in herds. On the other hand, the initial prevalence was not yet detected as a 
Table 2.  Evolution of TB incidence risk (IR) in BCG vaccinated goats from farms throughout the study. a Total 
of susceptible animals was calculated by the addition of the new vaccinated goat kids minus the half of the 
number of vaccinated animals that died or were slaughtered between sampling time points (we assumed that 
they were present a half of the period).
Farm
M0-M6 M6-M12 M12-M24 M24-M36
TB + Totala IR (%) TB + Total IR (%) TB + Total IR (%) TB + Total IR (%)
1 6 109 6 5 131 4 2 106 2 4 120 3
2 55 360 15 21 454 5 42 369 11 49 576 9
3 23 121 19 53 183 29 32 116 28 27 247 11
4 2 255 1 24 244 10 73 188 39 87 330 26
5 28 90 31 8 53 15 8 38 21 6 88 7
Table 3.  TB prevalence at month 36 of trial by age of vaccination of goats from farms 1, 2, 3 and 5. a Adult 
goats vaccinated with BCG at M0. bGoat kids vaccinated at 2–3 months of age throughout the trial.
TB + TB- Total % TB + at M36
Adulta 142 179 321 44%
Goat  kidsb 161 876 1037 16%
7
Vol.:(0123456789)
Scientific Reports |        (2020) 10:20369  | https://doi.org/10.1038/s41598-020-77334-1
www.nature.com/scientificreports/
Figure 3.  TB Incidence in BCG vaccinated batches from farms 1 (a), 2 (b), 3 (c), 4 (d) and 5 (e) throughout 
the trial. Proportion of TB negative animals (y axis) throughout the time in contact (x axis) with the TB positive 
herd in months. The table represents the incidence of TB in each batch (B) depending on the time in contact, 
between 0 and 12 months ([0–12]), more than 12–24 months ((12–24]) and more than 24–36 months ((24–36]). 
The animals at risk, which were the TB negative animals between sampling time points (some animals were 
slaughtered or died between periods. Those animals were considered present during the half of the period and 
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significant risk factor for TB infection in the herds, however, a high initial prevalence may increase the pressure 
of infection, hampering the positive effects of vaccination. Interestingly, BCG vaccinated goat kids that converted 
positively to IGRA did not appear to represent a risk for TB infection for other vaccinated animals. Probably 
these goats were less likely to infect other animals because they were partially protected and did not excrete or 
had reduced the mycobacterial  shedding16. Also, previous experimental infections with M. caprae showed slower 
progression of the TB infection, and a lower degree of lung lesions in BCG vaccinated goats compared to unvac-
cinated  controls30–32,50. This reduction of pathology does not favour the mycobacterial excretion by  coughing51. 
Thus, both the progressive slaughter of TB positive unvaccinated animals and the systematic BCG vaccination 
of replacement goat kids may contribute to the reduction of TB incidence and TB prevalence in goat farms. 
Furthermore, previous studies have identified a high census of  cattle28,52 and intensive  management53 as risk 
factors for TB disease. However, in our conditions, these factors did not show a significant impact on the risk of 
TB infection. It is important to remark that risk assessments should be taken with caution because sample size, 
the measures used, the variables analysed, and the size of herds may differ among  studies28.
Finally, the SICCT and the IGRA with tuberculins and DIVA reagents were used as indicators of TB infec-
tion in order to maximize the detection of infected animals prior to vaccination. However, as BCG vaccination 
causes interferences with the SICCT and the IGRA standard, at least after one year of  vaccination47, the only 
available diagnostic tool for the diagnosis of TB in vaccinated goats was the IGRA using DIVA reagents. The 
main caveat of this DIVA test in goats is that, the observed sensitivity in previous studies in TB infected goat 
Figure 3.  (continued)
Table 4.  Risk of TB infection per batch during the first year in contact with the TB positive herd. 1 Risk 
estimate coefficient of TB infection (± SE) between batches in farms 1, 2, 3 and 5, determined by a generalized 
mixed-effect model with post hoc Tukey comparisons between batches. a P = 0.0001, bP < 0.0001.
Comparisons between batches Risk  Estimate1
B-0 versus B-06 0.927 (± 0.186)a
B-0 versus B-12 19.78 (± 323.87)
B-0 versus B-24 1.89 (± 0.299)b
B-0 versus B-36 1.61 (± 0.219)b
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herds was around 70%25,27, despite being highly specific (100%)27. On the other hand, as responses developed 
against BCG vaccine contribute to the containment of the  infection30, it is possible that some vaccinated-infected 
animals do not develop a detectable response by the IGRA DIVA. Thus, up to 30% of false negatives among vac-
cinated animals had to be assumed in the present study and this could attenuate the intervallic incidence risk. 
However, the same criterion for positivity was used in all time-points, enabling to assess the vaccine efficacy by 
the evolution of TB prevalence and AF.
In conclusion, our results showed that systematic BCG vaccination of replacement goat kids could contribute 
to reducing the transmission of M. caprae, steady reducing the overall TB prevalence within the herds, even when 
individual vaccine efficacy decreased one year after vaccination. Moreover, removing positive unvaccinated goats 
from the herds reduced the risk of new TB cases, favouring the success of the vaccination program. Therefore, 
besides vaccination, additional measures, such as test and cull of positive animals, are strongly recommended. 
The present study provides relevant data to evaluate the cost–benefit of a long-term vaccination strategy to the 
control of caprine TB.
Material and methods
Study design and animals. The present research was carried out in the framework of preliminary stud-
ies to establish an action plan for the control and eradication of caprine TB of the Department of Agriculture, 
Livestock, Fisheries, and Food of the Catalan Government (DARP). It was a field trial including five goat farms 
from Catalonia (Spain) with confirmed TB infection by culture (M. caprae) from tuberculous lesions in necrop-
sied goats. Farms were selected due to the high proportion of positive animals detected in an initial screening 
carried out by the single-intradermal cervical comparative skin test (SICCT) (above 30% of positivity). The M. 
caprae strains (www.Mbovi s.org) from each farm are detailed in Table 5. Farms had different sizes, production, 
and management characteristics.
The trial was conducted for 36 months. At the initial test sampling (Month 0), all adult and young (> 6 months) 
goats were tested with SICCT and IGRA, using M. bovis and M. avium tuberculins (CZV vaccines, Porriño, 
Spain) and a reagent for differentiating infected from vaccinated (DIVA) based on ESAT-6 and CFP-10 MTBC 
antigens (Lionex, Braunschweig, Germany). Animals positive at least to one test were classified as positive, and 
animals negative to all tests were vaccinated subcutaneously with BCG Danish 1331 strain (ATCC, Ref. 35733) 
behind the axillar region. All replacement goat kids added to the herd during the trial were systematically vac-
cinated at 2–3 months of age, and batches (B) were named depending on the month of first entry on sampling 
routine (B-06, B-12, B-24, and B36, respectively). Replacement animals were managed in the herd following 
the productive routine of each farm. All goats with more than six months of age were tested at months (M) 6, 
12, 24, and 36 after the initial vaccination (at Month 0) by the IGRA with tuberculins and DIVA reagents. BCG 
vaccinated animals were considered as positive depending only on the results of the DIVA test.
Vaccine. The M. bovis BCG Danish 1331 strain (ATCC, Ref. 35,733) was prepared as described  previously30. 
Briefly, an aliquot of BCG was subcultured in the Middelbrook 7H9 medium (BD diagnostics, sparks MD USA) 
and incubated for 28 days at 37 °C. Then, an aliquot of the growth culture was tenfold diluted on phosphate-
buffered saline (PBS) with 0.05% Tween 80, and plated on 7H11 solid media (BD diagnostics) and incubated for 
28 days at 37 °C, then the remaining growth culture was divided in 1 ml aliquots that were stored at -80 °C. After 
incubation, the bacterial count was performed. For vaccine preparation, a suspension of one aliquot of growth 
culture was thawed and diluted in PBS to reach  approximately106 CFU/ml. An aliquot of 0.5 ml of this suspen-
sion was subcutaneously injected in goats, and an aliquot of 70 µl of the suspension was tenfold diluted to verify 
the titer of the vaccine (2–8 × 105 CFU/ml).
Single‑intradermal cervical comparative skin test (SICCT). Before intradermal inoculation, the area 
was shaved, and skinfold thickness (SFT) was measured. The SICCT was performed by intradermal inoculation 
of 0.1 ml of purified protein derivative from M. bovis (PPD-B) and M. avium (PPD-A) at 25,000 IU/ml each 
one, at the left-hand side and the right-hand side of the neck, respectively, by using a Dermojet syringe (Akra 
Dermojet, Pau, France). The increase of SFT was measured 72 h after inoculation. SICCT was interpreted as 
recommended by the Spanish bovine TB eradication  program54. A goat was considered a positive reactor if SFT 
PPD-B > 2 mm and SFT PPD-B—SFT PPD-A > 1 mm, or if the presence of clinical signs in the PPD-B inocula-
tion site.
Table 5.  Characteristics of goat farms. 1 Ecological farm (daily grazing for 8 h, no use of antibiotics).
Farm Breed No. of animals Production Management Replacement origin M. caprae spoligotype
1 Blanca de Rasquera 180 Meat Extensive Own SB0415
2 Malagueña 557 Milk Intensive Own SB0157
3 Murciana-granadina 458 Milk Intensive Mixed SB0415SB0157
4 Murciana-granadina/Alpine/mixed 434 Milk Intensive
1 Mixed SB0415
5 Mixed breeds 174 Milk Extensive Own SB0415
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Whole blood interferon‑gamma release assay (IGRA). Blood samples from the jugular vein were 
collected in heparinized tubes and were processed under 8  h of bleeding, as described  previously26. Briefly, 
blood samples were stimulated with PPD-A, PPD-B, and the DIVA reagent (ESAT-6/CFP10 cocktail) at a final 
concentration of 20 μg/ml each. PBS was used for the unstimulated control. Samples were then incubated over-
night at 37 ± 1 °C with 0.5%  CO2. Plasma supernatants were collected by centrifugation and analysed by ELISA 
(BOVIGAM, Thermo Fisher Scientific, Waltham, MA, USA) and read at 450 nm using a spectrophotometer 
(Biotek Power Wave XS). The tuberculin IGRA based test was interpreted as recommended by the manufacturer: 
an animal was considered positive if PPD-B OD – PBS OD ≥ 0.05 and PPD-B OD > PPD-A OD, and for the 
DIVA reagent, an animal was considered positive if ESAT-6/CFP-10 OD – PBS OD ≥ 0.05.
Parameters considered for the analysis. In order to assess the effects of BCG vaccination, different 
parameters were calculated:
• The prevalence (P), estimated as the percentage of TB cases (new and old) at each “i” sampling time.
• Prevalence reduction between each follow-up period: estimated on the basis of the attributable fraction (AF) 
between periods as follows:
• The incidence risk (IR) in BCG vaccinated animals at each “i” sampling time. In order to account for the 
animals that entered (new) or leaved (lost) the group of vaccinated animals (N) throughout each follow-up 
period, we followed this approximation:
Statistical analysis. Differences between the number of TB positive animals at the beginning of the study 
(Month 0) and the end of the study (Month 36) for each studied farm, were calculated using a chi-square test. A 
P-value < 0.05 was considered as significant.
In addition, differences in TB incidence risk among BCG vaccinated batches was evaluated taking into 
account the time in contact with infected animals of the herd of each vaccinated goat (i.e., less or more than one 
year, more than one year to two years, and more than two years to three years of being introduced in the TB 
positive farm) and the batch of animals. The time in contact was calculated based on the time that each animal 
remained negative on the farm. The interaction between both variables was included in the analysis. Besides, 
two qualitative variables (i.e., intensive or extensive management, high or low ventilated facilities) and five 
quantitative variables (i.e., number of unvaccinated animals in herds at the end of the study, initial prevalence, 
initial census, vaccinated positive adult and goat kids at the end of the study) were also considered. At a first 
step, we fit a generalized mixed-effect model with a Poisson error structure (as the number of cases is a count 
variable) separately for each variable. Variables with significant influence (P < 0.05) or with P < 0.3, were selected. 
In a second step, a multilevel model, also with a Poisson error structure, was fit, which included the farm as a 
random effect to take into account the lack of independence of the observations. Model selection was based on 
the Akaike information criterion (AIC), starting with a complex model including all variables with significant 
influence. Then, the complexity of the model was reduced by removing one by one of the variables without sig-
nificant influence (based on P- values > 0.05). The AIC’s of models generated were compared. Finally, the model 
with the lowest AIC was selected, and Tukey comparisons were performed in order to compare the incidence 
risk among batches depending on the time of exposure. All the analyses were performed using RStudio Team 
(2019). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL: https ://www.rstud io.com/.
Ethics approval. All procedures were approved by the Research Ethics Commission of the Generalitat de 
Catalunya (procedure number 8697). All animals were managed by the personnel of the farm following conven-
tional procedures and qualified veterinarians, authorized by the Departament d’Agricultura, Ramaderia, Pesca 
i Alimentació de la Generalitat de Catalunya (DARP), performed testing and sampling according to European 
(86/609/CEE) and Spanish (RD 53/2013) legislation.
Data availability
The databases generated and analyzed during the current study are available from the corresponding author on 
a reasonable request.
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